세계의 저인산증 치료 시장 보고서(2025년)
Hypophosphatasia Treatment Global Market Report 2025
상품코드 : 1821682
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

저인산증 치료 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 5.7%를 나타내 36억 8,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 새로운 치료법, 환자 수 증가, 정밀의료 동향, 정부의 이니셔티브, 질병에 대한 의식 증가에 기인합니다. 예측 기간의 주요 동향으로는 치료방법의 진보, 연구개발 이니셔티브, 시장 확대와 세계 전개, 공동연구와 파트너십, 규제상황 등이 있습니다.

향후 5년간의 성장률 5.7%라고 하는 예측은 전회 예측으로부터 0.2%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 부과로 미국에서는 프랑스와 벨기에에서 수입되는 저인산혈증을 위한 효소 보충 요법에 대한 접근이 방해되어 소아의 골 장애가 악화되어 대사성 질환의 치료비가 증가할 수 있습니다. 또한 상호 관세와 무역 긴장 증가와 제한으로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 더 광범위하게 늘어날 것으로 보입니다.

예상되는 저인산증 치료 시장 성장은 생물 의학 연구 활동에 대한 투자 증가로 이어집니다. 이러한 투자는 과학적 연구 기술을 통해 생물의학의 이론을 검증하고 인간의 건강에 대한 독특한 측면에 대한 지식을 확대하는 데 참여하고 있습니다. 생물의학 연구 투자는 드문 유전성 골 질환인 저인산증의 효율적이고 개선된 치료를 위한 신약 및 치료법의 개발에 중요한 역할을 합니다. 메디케어 및 메디케이드 서비스 센터가 2023년 9월에 보고한 것처럼 미국의 국민 의료비는 2021년에 2.7% 증가했고 4조 3,000억 달러에 달했습니다. 2022년부터 2031년까지 국민의료비 예측 평균 성장률은 5.4%를 나타내 GDP의 평균 성장률 4.6%를 상회할 것으로 예상됩니다. 이 궤적에 따라 GDP에서 차지하는 의료비의 비율은 2021년의 18.3%에서 2031년에는 19.6%로 증가할 것으로 예측됩니다. 따라서 생물 의학 연구 투자 증가는 저인산증 치료 시장 성장의 중요한 촉진요인입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Hypophosphatasia treatment involves addressing an inherited disorder that affects the development of bones and teeth, also known as Rathbun disease. This disorder disrupts the mineralization process, impacting the deposition of calcium and phosphorus in developing bones and teeth.

The major types of hypophosphatasia disorders include odontohypophosphatasia, pseudohypophosphatasia, and others, and they can be treated through various methods such as enzyme replacement therapies, medications, and surgeries. Odontohypophosphatasia is a specific subtype of hypophosphatasia (HPP) characterized by lower activity of unfractionated serum alkaline phosphatase, premature exfoliation of primary and permanent teeth, and severe dental caries. Treatment methods may be administered orally or through injections. Distribution channels for these treatments include hospital pharmacies, online pharmacies, and retail pharmacies, catering to end users such as hospitals, homecare, specialty clinics, among others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The hypophosphatasia treatment market research report is one of a series of new reports from The Business Research Company that provides hypophosphatasia treatment market statistics, including hypophosphatasia treatment industry global market size, regional shares, competitors with a hypophosphatasia treatment market share, detailed hypophosphatasia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the hypophosphatasia treatment industry. This hypophosphatasia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hypophosphatasia treatment market size has grown steadily in recent years. It will grow from $2.83 billion in 2024 to $2.95 billion in 2025 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to limited treatment options, increasing awareness, globalization of clinical trials, healthcare infrastructure development, investments and funding.

The hypophosphatasia treatment market size is expected to see strong growth in the next few years. It will grow to $3.68 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to emerging therapies, increasing patient pool, precision medicine trends, government initiatives, increasing disease awareness. Major trends in the forecast period include advancements in therapeutic approaches, research and development initiatives, market expansion and global reach, collaborations and partnerships, regulatory landscape.

The forecast of 5.7% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. access to enzyme replacement therapies for hypophosphatasia imported from France and Belgium, potentially worsening pediatric bone disorders and increasing metabolic disease treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated growth of the hypophosphatasia treatment market is driven by the increasing investments in biomedical research activities. These investments involve verifying biomedical science theories through scientific research techniques and expanding knowledge about unique aspects of human health. Biomedical research investments play a crucial role in developing new drugs and therapies for the efficient and improved treatment of hypophosphatasia, a rare inherited bone disorder. As reported by the Centers for Medicare & Medicaid Services in September 2023, national health expenditure in the United States experienced a 2.7% growth in 2021, reaching $4.3 trillion. The average projected growth in national health expenditure from 2022 to 2031 is 5.4%, surpassing the average GDP growth of 4.6%. This trajectory is expected to result in an increased health spending share of GDP from 18.3% in 2021 to 19.6% in 2031. Thus, the rise in biomedical research investments is a significant driver for the growth of the hypophosphatasia treatment market.

The anticipated growth of the hypophosphatasia treatment market is also attributed to the increasing geriatric population. The geriatric population, comprising individuals aged 65 years and above, contributes to the demand for hypophosphatasia-related healthcare services. This includes early diagnosis and long-term management, driving advancements in understanding and treating this condition within the aging demographic. According to the World Health Organization (WHO) report in October 2022, one in six people worldwide is expected to be 60 or older by 2030, and by 2050, there will be 2.1 billion people aged 60 or older. Therefore, the growing geriatric population is a significant factor propelling the hypophosphatasia treatment market.

Leading companies in the hypophosphatasia treatment market are concentrating on the development of innovative therapies, such as engineered B Cell Medicines and enzyme replacement therapies, to improve patient outcomes and manage this rare genetic disorder more effectively. B Cell Medicines (BCMs) are engineered therapeutic strategies that use modified B cells to produce and release therapeutic proteins, offering potential solutions for various diseases, including genetic disorders and cancers. For example, in June 2024, Be Biopharma, Inc., a U.S.-based firm specializing in B cell medicines for severe diseases, presented promising preclinical data on a novel B Cell Medicine (BCM) aimed at treating Hypophosphatasia (HPP), a rare genetic disorder caused by a deficiency in tissue-nonspecific alkaline phosphatase (ALP). This research emphasizes the innovative application of CRISPR/Cas9-based precision gene engineering, combined with artificial intelligence-guided protein design, to enhance the therapeutic potential of BCMs.

Major players in the hypophosphatasia treatment market are focusing on novel therapeutic approaches, such as ENPP1 inhibitors, to promote bone mineralization and enhance the quality of life for patients suffering from this rare genetic disorder. ENPP1 inhibition involves blocking the enzyme ENPP1, which lowers inorganic pyrophosphate (PPi) levels, thereby improving bone mineralization and offering a potential therapy for hypophosphatasia (HPP). For instance, in September 2024, Rallybio, a U.S.-based biotechnology company, released nonclinical data demonstrating ENPP1 inhibition as a therapeutic method for treating patients with hypophosphatasia (HPP). This therapy addresses the unmet medical need for effective treatments for both adult and pediatric populations affected by HPP.

In March 2024, AstraZeneca plc, a UK-based pharmaceutical firm, acquired Fusion Pharmaceuticals Inc. for an undisclosed amount. Through this acquisition, AstraZeneca aims to strengthen its oncology portfolio by incorporating innovative next-generation radio conjugates to provide more targeted cancer therapies, thereby enhancing patient outcomes and solidifying its market presence. Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company based in Canada that develops precision medicines for cancer.

Major companies operating in the hypophosphatasia treatment market include Kirin Holdings Company Limited, Vericel Corporation, Mereo Biopharma Group plc, Novartis AG, AM-Pharma B.V., Bayer AG, Pfizer Inc., Ultragenyx Pharmaceutical Inc., BioMarin Pharmaceutical Inc., AstraZeneca plc, Rallybio Corporation, AbCellera Biologics Inc., Inozyme Pharma Inc., Aruvant Sciences Pte. Ltd., Asfotase Alfa, Merck Co. & KGaA, Kyowa Kirin Co.Ltd., Shire plc, Sanofi S.A., GlaxoSmithKline plc, Eli Lilly and Company, Roche Holding AG, Johnson & Johnson Services Inc., AbbVie Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, Gilead Sciences Inc., Incyte Corporation, Ipsen S.A., Jazz Pharmaceuticals plc, Mallinckrodt Pharmaceuticals, Regeneron Pharmaceuticals Inc.

North America was the largest region in the hypophosphatasia treatment market in 2024. The regions covered in the hypophosphatasia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hypophosphatasia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hypophosphatasia treatment market consists of revenues earned by entities by providing hypophosphatasia treatment services, such as regular dental care, physical and occupational therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The hypophosphatasia treatment market also includes sales of nonsteroidal anti-inflammatory drugs (NSAIDs) and vitamin B6 tablets or capsules which are used in providing hypophosphatasia treatment. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hypophosphatasia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hypophosphatasia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for hypophosphatasia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hypophosphatasia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Hypophosphatasia Treatment Market Characteristics

3. Hypophosphatasia Treatment Market Trends And Strategies

4. Hypophosphatasia Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Hypophosphatasia Treatment Growth Analysis And Strategic Analysis Framework

6. Hypophosphatasia Treatment Market Segmentation

7. Hypophosphatasia Treatment Market Regional And Country Analysis

8. Asia-Pacific Hypophosphatasia Treatment Market

9. China Hypophosphatasia Treatment Market

10. India Hypophosphatasia Treatment Market

11. Japan Hypophosphatasia Treatment Market

12. Australia Hypophosphatasia Treatment Market

13. Indonesia Hypophosphatasia Treatment Market

14. South Korea Hypophosphatasia Treatment Market

15. Western Europe Hypophosphatasia Treatment Market

16. UK Hypophosphatasia Treatment Market

17. Germany Hypophosphatasia Treatment Market

18. France Hypophosphatasia Treatment Market

19. Italy Hypophosphatasia Treatment Market

20. Spain Hypophosphatasia Treatment Market

21. Eastern Europe Hypophosphatasia Treatment Market

22. Russia Hypophosphatasia Treatment Market

23. North America Hypophosphatasia Treatment Market

24. USA Hypophosphatasia Treatment Market

25. Canada Hypophosphatasia Treatment Market

26. South America Hypophosphatasia Treatment Market

27. Brazil Hypophosphatasia Treatment Market

28. Middle East Hypophosphatasia Treatment Market

29. Africa Hypophosphatasia Treatment Market

30. Hypophosphatasia Treatment Market Competitive Landscape And Company Profiles

31. Hypophosphatasia Treatment Market Other Major And Innovative Companies

32. Global Hypophosphatasia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hypophosphatasia Treatment Market

34. Recent Developments In The Hypophosphatasia Treatment Market

35. Hypophosphatasia Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기